Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Akamai Technologies, Inc. (AKAM) vs Becton Dickinson and Co (BDX) Price & Performance

Akamai Technologies, Inc.Trade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

Akamai Technologies, Inc. vs Becton Dickinson and Co — how do they compare? Akamai Technologies, Inc. trades at $122.5 (market cap $16.77B), while Becton Dickinson and Co trades at $181.29 (market cap $49.41B). The key difference: Becton Dickinson and Co is far larger — about 2.9× Akamai Technologies, Inc.'s market cap, and Becton Dickinson and Co pays a 2.32% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.

AKAMBDX
Market Cap
$16.77B$49.41B
Sector
TechnologyHealth
52-Week High
$161.14$185.39
52-Week Low
$71.97$138.62
Enterprise Value
$22.75B$65.51B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Akamai Technologies, Inc.

Akamai Technologies (AKAM) trades at $122.67, up 4.27% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with $4.21B revenue and 57.45% gross margins. Recent analyst upgrades and a $600M cloud contract highlight growth potential in AI and cybersecurity services.

Outlook remains cautiously optimistic with a $150.11 consensus price target offering 22% upside, though margin compression and competitive pressures present risks. Institutional sentiment leans neutral with 49% hold ratings, requiring monitoring of Q3 earnings execution and infrastructure investment returns.

Becton Dickinson and Co

BDX trades at $183.71, up 2.27% today, near its consensus price target of $183.00. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $21.84 billion in 2025, with consistent earnings beats in recent quarters, including Q3 2026 EPS of $3.23 beating estimates. The company maintains a dividend of $1.05 per share and recently raised full-year guidance, reflecting operational strength amid tariff pressures.

Outlook remains positive with raised profit guidance and segment growth, but risks include margin pressure from tariffs and a product recall. Analyst sentiment is mixed with 47% buy ratings, suggesting cautious optimism. The stock offers stability as a Dividend Aristocrat with growth catalysts from medical technology advancements, though investors should monitor margin trends and competitive dynamics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Akamai Technologies, Inc.

Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.

Read more on AKAM

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX